These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 22212680)

  • 1. Targeting proteinase-activated receptors: therapeutic potential and challenges.
    Ramachandran R; Noorbakhsh F; Defea K; Hollenberg MD
    Nat Rev Drug Discov; 2012 Jan; 11(1):69-86. PubMed ID: 22212680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of agonists/antagonists for protease-activated receptors (PARs) and the possible therapeutic application to gastrointestinal diseases].
    Sekiguchi F
    Yakugaku Zasshi; 2005 Jun; 125(6):491-8. PubMed ID: 15930817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.
    Hansen KK; Oikonomopoulou K; Li Y; Hollenberg MD
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):377-92. PubMed ID: 17952408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Opportunities in Protease-Activated Receptor Drug Development.
    Hamilton JR; Trejo J
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():349-373. PubMed ID: 27618736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.
    Hollenberg MD; Mihara K; Polley D; Suen JY; Han A; Fairlie DP; Ramachandran R
    Br J Pharmacol; 2014 Mar; 171(5):1180-94. PubMed ID: 24354792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.
    Hollenberg MD; Oikonomopoulou K; Hansen KK; Saifeddine M; Ramachandran R; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):643-51. PubMed ID: 18627296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinases as hormones: targets and mechanisms for proteolytic signaling.
    Hansen KK; Oikonomopoulou K; Baruch A; Ramachandran R; Beck P; Diamandis EP; Hollenberg MD
    Biol Chem; 2008 Aug; 389(8):971-82. PubMed ID: 18979623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing PAR1 antagonists: minding the endothelial gap.
    Ramachandran R
    Discov Med; 2012 Jun; 13(73):425-31. PubMed ID: 22742648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential signaling by protease-activated receptors: implications for therapeutic targeting.
    Sidhu TS; French SL; Hamilton JR
    Int J Mol Sci; 2014 Apr; 15(4):6169-83. PubMed ID: 24733067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.
    Ramachandran R; Hollenberg MD
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S263-82. PubMed ID: 18059329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in synthesis of PAR ligands as therapeutic strategy for inflammatory diseases.
    Severino B; Santagada V; Perissutti E; Fiorino F; Frecentese F; De Angelis F; Esposito A; Caliendo G
    Mini Rev Med Chem; 2009 Jun; 9(6):653-63. PubMed ID: 19519491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonists and antagonists of protease activated receptors (PARs).
    Barry GD; Le GT; Fairlie DP
    Curr Med Chem; 2006; 13(3):243-65. PubMed ID: 16475935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease.
    Lee H; Hamilton JR
    Pharmacol Ther; 2012 May; 134(2):246-59. PubMed ID: 22327235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease-activated receptors: potential therapeutic targets in irritable bowel syndrome?
    Gloro R; Ducrotte P; Reimund JM
    Expert Opin Ther Targets; 2005 Oct; 9(5):1079-95. PubMed ID: 16185159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinase-activated receptors in the nervous system.
    Noorbakhsh F; Vergnolle N; Hollenberg MD; Power C
    Nat Rev Neurosci; 2003 Dec; 4(12):981-90. PubMed ID: 14682360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.
    Caliendo G; Santagada V; Perissutti E; Severino B; Fiorino F; Frecentese F; Juliano L
    J Med Chem; 2012 Aug; 55(15):6669-86. PubMed ID: 22607152
    [No Abstract]   [Full Text] [Related]  

  • 17. Signal transduction by protease-activated receptors.
    Soh UJ; Dores MR; Chen B; Trejo J
    Br J Pharmacol; 2010 May; 160(2):191-203. PubMed ID: 20423334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the understanding of protease-activated receptors.
    Gabazza EC; Taguchi O; Kamada H; Hayashi T; Adachi Y; Suzuki K
    Int J Hematol; 2004 Feb; 79(2):117-22. PubMed ID: 15005337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease-activated receptors (PARs) are partly pro-inflammatory and partly anti-inflammatory: will PAR agonists or antagonists participate in future drug therapies?
    De Campo BA; Henry PJ
    Curr Drug Targets; 2006 May; 7(5):629-37. PubMed ID: 16719772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Union of Pharmacology. XXVIII. Proteinase-activated receptors.
    Hollenberg MD; Compton SJ
    Pharmacol Rev; 2002 Jun; 54(2):203-17. PubMed ID: 12037136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.